EASD 2009: Lantus defended amid allegations of increased cancer risk
It presenters at the conference discussed the current evidence and its limitations. However, a potential mechanism by which insulin could promote cancer cell growth was also proposed. ( http://www.bharatbook.com/detail.asp?id=91847&rt=Commercial-Insight-Cardiovascular-and-Metabolic-Market-Overview-Diabetes-to-the-fore-as-generics-hit-primary-care-markets.html )
Although the European Association for the Study of Diabetes (EASD) recommended the continued use of Lantus in type 1 and type 2 diabetics, it has called for increased research into the relationship between insulin therapy – particularly Lantus (insulin glargine; Sanofi-Aventis) – and the risk of cancer.
It was postulated during the discussion at the 2009 EASD meeting that insulin use may be related to the increased incidence of cancer seen in diabetics over that seen in the general population. The preliminary data discussed in the symposium suggested lower rates of cancer with Levemir (insulin detemir; Novo Nordisk) compared to neutral protamine Hagedorn (NPH), but higher rates with Lantus. Continue reading ‘EASD 2009 – Lantus defended amid allegations of increased cancer risk’ »